TScan: FDA OKs Investigational New Drug Application for Leukemia

Phase 1 trial of TSC-100 expected to initiate in the first half of 2022 –

– IND for TSC-101 on hold pending additional assessment of the risk of off-tumor reactivity –

 TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate TSC-100 for the treatment of patients with hematologic malignancies who are undergoing allogeneic hematopoietic cell transplantation (HCT). The target of TSC-100 is the minor histocompatibility antigen HA-1, which is a lineage-specific antigen found on blood cells. The Company will now submit the clinical protocol to Institutional Review Boards (IRB) for the initial study sites and expects to begin dosing patients in the first half of 2022.

https://finance.yahoo.com/news/tscan-therapeutics-announces-fda-clearance-120000327.html